148 research outputs found
The field and microstructural signatures of deformation‐assisted melt transfer: Insights from magmatic arc lower crust, New Zealand
Melt must transfer through the lower crust, yet the field signatures and mechanisms involved in such transfer zones (excluding dykes) are still poorly understood. We report field and microstructural evidence of a deformation‐assisted melt transfer zone that developed in the lower crustal magmatic arc environment of Fiordland, New Zealand. A 30–40 m wide hornblende‐rich body comprising hornblende ± clinozoisite and/or garnet exhibits 'igneous‐like' features and is hosted within a metamorphic, two‐pyroxene–pargasite gabbroic gneiss (GG). Previous studies have interpreted the hornblende‐rich body as an igneous cumulate or a mass transfer zone. We present field and microstructural characteristics supporting the later and indicating the body has formed by deformation‐assisted, channelized, reactive porous melt flow. The host granulite facies GG contains distinctive rectilinear dykes and garnet reaction zones (GRZ) from earlier in the geological history; these form important reaction and strain markers. Field observations show that the mineral assemblages and microstructures of the GG and GRZ are progressively modified with proximity to the hornblende‐rich body. At the same time, GRZ bend systematically into the hornblende‐rich body on each side of the unit, showing apparent sinistral shearing. Within the hornblende‐rich body itself, microstructures and electron back‐scatter diffraction mapping show evidence of the former presence of melt including observations consistent with melt crystallization within pore spaces, elongate pseudomorphs of melt films along grain boundaries, minerals with low dihedral angles as small as <10° and up to <60°, and interconnected 3D melt pseudomorph networks. Reaction microstructures with highly irregular contact boundaries are observed at the field and thin‐section scale in remnant islands of original rock and replaced grains, respectively. We infer that the hornblende‐rich body was formed by modification of the host GG in situ due to reaction between an externally derived, reactive, hydrous gabbroic to intermediate melt percolating via porous melt flow through an actively deforming zone. Extensive melt–rock interaction and metasomatism occurred via coupled dissolution–precipitation, triggered by chemical disequilibrium between the host rock and the fluxing melt. As a result, the host plagioclase and pyroxene became unstable and were reacted and dissolved into the melt, while hornblende and to a lesser extent clinozoisite and garnet grew replacing the unstable phases. Our study shows that hornblendite rocks commonly observed within deep crustal sections, and attributed to cumulate fractionation processes, may instead delineate areas of deformation‐assisted, channelized reactive porous melt flow formed by melt‐mediated coupled dissolution–precipitation replacement reactions
Petrogenesis and geochronology of a post-orogenic calc-alkaline magmatic association: the Žulová Pluton, Bohemian Massif
Biallelic MLH1 SNP cDNA expression or constitutional promoter methylation can hide genomic rearrangements causing Lynch syndrome
A positive family history, germline mutations in DNA mismatch repair genes, tumours with high microsatellite instability, and loss of mismatch repair protein expression are the hallmarks of hereditary non-polyposis colorectal cancer (Lynch syndrome). However, in ~10-15% of cases of suspected Lynch syndrome, no disease-causing mechanism can be detected
HNPCC: Six new pathogenic mutations
BACKGROUND: Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominant disease with a high risk for colorectal and endometrial cancer caused by germline mutations in DNA mismatch-repair genes (MMR). HNPCC accounts for approximately 2 to 5% of all colorectal cancers. Here we present 6 novel mutations in the DNA mismatch-repair genes MLH1, MSH2 and MSH6. METHODS: Patients with clinical diagnosis of HNPCC were counselled. Tumor specimen were analysed for microsatellite instability and immunohistochemistry for MLH1, MSH2 and MSH6 protein was performed. If one of these proteins was not detectable in the tumor mutation analysis of the corresponding gene was carried out. RESULTS: We identified 6 frameshift mutations (2 in MLH1, 3 in MSH2, 1 in MSH6) resulting in a premature stop: two mutations in MLH1 (c.2198_2199insAACA [p.N733fsX745], c.2076_2077delTG [p.G693fsX702]), three mutations in MSH2 (c.810_811delGT [p.C271fsX282], c.763_766delAGTGinsTT [p.F255fsX282], c.873_876delGACT [p.L292fsX298]) and one mutation in MSH6 (c.1421_1422dupTG [p.C475fsX480]). All six tumors tested for microsatellite instability showed high levels of microsatellite instability (MSI-H). CONCLUSIONS: HNPCC in families with MSH6 germline mutations may show an age of onset that is comparable to this of patients with MLH1 and MSH2 mutations
Lectures on the functional renormalization group method
These introductory notes are about functional renormalization group equations
and some of their applications. It is emphasised that the applicability of this
method extends well beyond critical systems, it actually provides us a general
purpose algorithm to solve strongly coupled quantum field theories. The
renormalization group equation of F. Wegner and A. Houghton is shown to resum
the loop-expansion. Another version, due to J. Polchinski, is obtained by the
method of collective coordinates and can be used for the resummation of the
perturbation series. The genuinely non-perturbative evolution equation is
obtained in a manner reminiscent of the Schwinger-Dyson equations. Two variants
of this scheme are presented where the scale which determines the order of the
successive elimination of the modes is extracted from external and internal
spaces. The renormalization of composite operators is discussed briefly as an
alternative way to arrive at the renormalization group equation. The scaling
laws and fixed points are considered from local and global points of view.
Instability induced renormalization and new scaling laws are shown to occur in
the symmetry broken phase of the scalar theory. The flattening of the effective
potential of a compact variable is demonstrated in case of the sine-Gordon
model. Finally, a manifestly gauge invariant evolution equation is given for
QED.Comment: 47 pages, 11 figures, final versio
Scale-free static and dynamical correlations in melts of monodisperse and Flory-distributed homopolymers: A review of recent bond-fluctuation model studies
It has been assumed until very recently that all long-range correlations are
screened in three-dimensional melts of linear homopolymers on distances beyond
the correlation length characterizing the decay of the density
fluctuations. Summarizing simulation results obtained by means of a variant of
the bond-fluctuation model with finite monomer excluded volume interactions and
topology violating local and global Monte Carlo moves, we show that due to an
interplay of the chain connectivity and the incompressibility constraint, both
static and dynamical correlations arise on distances . These
correlations are scale-free and, surprisingly, do not depend explicitly on the
compressibility of the solution. Both monodisperse and (essentially)
Flory-distributed equilibrium polymers are considered.Comment: 60 pages, 49 figure
MicroRNA-196a & microRNA-101 expression in Barrett's oesophagus in patients with medically and surgically treated gastro-oesophageal reflux
<p>Abstract</p> <p>Background</p> <p>Proton pump inhibitor (PPI) medication and surgical fundoplication are used for the control of gastro-oesophageal reflux in patients with Barrett's oesophagus, but differ in their effectiveness for both acid and bile reflux. This might impact on the inflammatory processes that are associated with progression of Barrett's oesophagus to cancer, and this may be evident in the gene expression profile and microRNA expression pattern in Barrett's oesophagus mucosa. We hypothesised that two miRNAs with inflammatory and oncogenic roles, miR-101 and miR-196a, are differentially expressed in Barrett's oesophagus epithelium in patients with reflux treated medically vs. surgically.</p> <p>Findings</p> <p>Mucosal tissue was obtained at endoscopy from patients with Barrett's oesophagus whose reflux was controlled by proton pump inhibitor (PPI) therapy (n = 20) or by fundoplication (n = 19). RNA was extracted and the expression of miR-101 and miR-196a was measured using real-time reverse transcription - polymerase chain reaction. There were no significant differences in miR-101 and miR-196a expression in Barrett's oesophagus epithelium in patients treated by PPI vs. fundoplication (p = 0.768 and 0.211 respectively). Secondary analysis showed a correlation between miR-196a expression and Barrett's oesophagus segment length (p = 0.014).</p> <p>Conclusion</p> <p>The method of reflux treatment did not influence the expression of miR-101 and miR-196a in Barrett's oesophagus. This data does not provide support to the hypothesis that surgical treatment of reflux better prevents cancer development in Barrett's oesophagus. The association between miR-196a expression and Barrett's oesophagus length is consistent with a tumour promoting role for miR-196a in Barrett's oesophagus.</p
Surveillance of FAP: a prospective blinded comparison of capsule endoscopy and other GI imaging to detect small bowel polyps
Background: Familial adenomatous polyposis (FAP) is a hereditary disorder characterized by polyposis along the gastrointestinal tract. Information on adenoma status below the duodenum has previously been restricted due to its inaccessibility in vivo. Ca
Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa
Aberrant CpG island (CGI) methylation occurs early in colorectal neoplasia. Quantitative methylation-specific PCR profiling applied to biopsies was used to quantify low levels of CGI methylation of 18 genes in the morphologically normal colonic mucosa of neoplasia-free subjects, adenomatous polyp patients, cancer patients and their tumours. Multivariate statistical analyses distinguished tumour from mucosa with a sensitivity of 78.9% and a specificity of 100% (P=3 × 10−7). In morphologically normal mucosa, age-dependent CGI methylation was observed for APC, AXIN2, DKK1, HPP1, N33, p16, SFRP1, SFRP2 and SFRP4 genes, and significant differences in CGI methylation levels were detected between groups. Multinomial logistic regression models based on the CGI methylation profiles from normal mucosa correctly identified 78.9% of cancer patients and 87.9% of non-cancer (neoplasia-free+polyp) patients (P=4.93 × 10−7) using APC, HPP1, p16, SFRP4, WIF1 and ESR1 methylation as the most informative variables. Similarly, CGI methylation of SFRP4, SFRP5 and WIF1 correctly identified 61.5% of polyp patients and 78.9% of neoplasia-free subjects (P=0.0167). The apparently normal mucosal field of patients presenting with neoplasia has evidently undergone significant epigenetic modification. Methylation of the genes selected by the models may play a role in the earliest stages of the development of colorectal neoplasia
NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma
BACKGROUND: Somatic genetic CDKN2A, TP53, and DNA content abnormalities are common in many human cancers and their precursors, including esophageal adenocarcinoma (EA) and Barrett's esophagus (BE), conditions for which aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have been proposed as possible chemopreventive agents; however, little is known about the ability of a biomarker panel to predict progression to cancer nor how NSAID use may modulate progression. We aimed to evaluate somatic genetic abnormalities with NSAIDs as predictors of EA in a prospective cohort study of patients with BE. METHODS AND FINDINGS: Esophageal biopsies from 243 patients with BE were evaluated at baseline for TP53 and CDKN2A (p16) alterations, tetraploidy, and aneuploidy using sequencing; loss of heterozygosity (LOH); methylation-specific PCR; and flow cytometry. At 10 y, all abnormalities, except CDKN2A mutation and methylation, contributed to EA risk significantly by univariate analysis, ranging from 17p LOH (relative risk [RR] = 10.6; 95% confidence interval [CI] 5.2–21.3, p < 0.001) to 9p LOH (RR = 2.6; 95% CI 1.1–6.0, p = 0.03). A panel of abnormalities including 17p LOH, DNA content tetraploidy and aneuploidy, and 9p LOH was the best predictor of EA (RR = 38.7; 95% CI 10.8–138.5, p < 0.001). Patients with no baseline abnormality had a 12% 10-y cumulative EA incidence, whereas patients with 17p LOH, DNA content abnormalities, and 9p LOH had at least a 79.1% 10-y EA incidence. In patients with zero, one, two, or three baseline panel abnormalities, there was a significant trend toward EA risk reduction among NSAID users compared to nonusers (p = 0.01). The strongest protective effect was seen in participants with multiple genetic abnormalities, with NSAID nonusers having an observed 10-y EA risk of 79%, compared to 30% for NSAID users (p < 0.001). CONCLUSIONS: A combination of 17p LOH, 9p LOH, and DNA content abnormalities provided better EA risk prediction than any single TP53, CDKN2A, or DNA content lesion alone. NSAIDs are associated with reduced EA risk, especially in patients with multiple high-risk molecular abnormalities
- …